NCT06639282 Repurposing Siponimod for Alzheimer's Disease
| NCT ID | NCT06639282 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | St. Joseph's Hospital and Medical Center, Phoenix |
| Condition | Alzheimer Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 105 participants |
| Start Date | 2025-08-26 |
| Primary Completion | 2029-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 105 participants in total. It began in 2025-08-26 with a primary completion date of 2029-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Collaboration with multiple sclerosis (MS) specialty colleagues led us to formulate the central hypothesis that Siponimod could lower the rate of brain atrophy in Alzheimer's disease (AD) subjects. To test our central hypothesis, we will carry out an 18-month Phase II, double-blind, randomized, twoarmed, placebo controlled, proof-of-concept clinical study in early AD subjects (i.e. mild AD) who will be receiving an escalating dose of Siponimod or placebo in the ratio 2:1 for 12 months, followed by a 6-month washout period. The primary outcome measures are safety and tolerability of Siponimod in mild AD subjects. The secondary outcome measures are the rates of brain atrophy derived from volumetric MRI (vMRI) as a proxy for neurodegeneration conducted at baseline, 6, 12, and 18 months. The tertiary outcome measures are the changes in cognition and the levels of AD-associated (e.g., Aβ and tau) and inflammatory biomarkers in CSF after Siponimod exposure. In an exploratory effort, we will also measure plasma inflammatory markers during the entire duration of the study to investigate whether one or more of these markers can be used as dynamic surrogate markers of treatment response. Using our unique experience with the repurposing of immunomodulatory drugs for AD (and NCT #04032626), in the present project we are using elements of clinical trial design that we believe were successful and made some adjustments to fit the pharmacologic and toxic properties of Siponimod.
Eligibility Criteria
Inclusion Criteria: 1. Male or female at least 50 years of age, but less than 85 (84 at time of screening) 2. Females must be of non-childbearing potential or have negative pregnancy test at time of screening. Women of non-childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy or bilateral salpingectomy) or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for \>12 months prior to the planned date of enrollment. 3. Must have a diagnosis of mild Alzheimer's Dementia determined by medical record review. 4. Vision and hearing must be sufficient to comply with study procedures. 5. Be able to take oral medications. 6. Must be able to attend all study visits indicated in the schedule of visits. 7. Must have a collateral informant/study partner who has significant direct contact with the patient at least 10 hours per week and who is willing to accompany the patient to specified clinic visits, supervise administration of all study medication, and be available for telephone visits/interviews. 8. Documented Mini Mental State Exam (MMSE) score between 20-26 at Screening Visit Day 1. 9. CT or MRI scan of the brain within 12 months of Screening Visit Day 1 showing no evidence of significant focal lesions or other pathology which could contribute to dementia. If neither a CT or a MRI scan is available from the past 12 months, a scan fulfilling the requirements must be obtained before randomization. 10. Hachinski ischemic score must be \< 4. 11. Geriatric depression scale must be \< 10. 12. Prior to dosing all randomized study subjects must show proof they have received immunization to varicella (VZV IgG). 13. Each patient must be assessed for capacity to consent by the principal or sub-investigators in order to provide informed consent. If the patient is deemed unable to provide informed consent, they must have a legally authorized representative (LAR), and the LAR must review and sign the informed consent form. If the patient does not have a LAR, the patient must appear able to provide informed consent and must review and sign the informed consent form. If the patient is deemed unable to provide informed consent and does not have a LAR, they cannot participate in the study. In addition, the patient's study partner/informant (as defined in the study inclusion criteria) must sign the informed consent form. If the LAR and the patient's study partner/informant are the same individual, he/she should sign under both. 14. No active suicidality identified on Columbia-Suicide Severity Rating Scale (C-SSRS). 15. Patients with stable prostate cancer may be included at the discretion of the Medical Monitor. 16. Patients who are on monoclonal antibody medication for the treatment of Alzheimer's (ex. lecanemab, donanemab) for \> 6 months or have discontinued monoclonal antibody medication for the treatment of Alzheimer's for \> 6 months may be included if all other criteria has been met. Exclusion Criteria: 1. Taking one of the following medications: Medications for treatment of cancer or other drugs that weaken the immune system (ex. Natalizumab and Rituximab), Amiodarone, Bishydroxycoumarin, Chloramphenicol, Cimetidine, Fluconazole, Fluvastatin, Miconazole, Phenylbutazone, Sulphinpyrazone, Sulphadiazine, Sulphamethizole, Sulfamethoxazole, Sulphaphenazole, Trimethoprim, and Zafirlukast. 2. Current active infection in participants including, but not limited to, herpes zoster, herpes infection, bronchitis, sinusitis, upper respiratory infection and fungal skin infection. Siponimod may increase the risk in participants with active infections. 3. If participant received mRNA COVID-19 vaccination, must have received last dose at least 3 months prior to first dose of study drug/placebo. 4. Current evidence or history within the last 3 years of a neurological or psychiatric illness that could contribute to dementia, including (but not limited to) epilepsy, focal brain lesion, Parkinson's disease, seizure disorder, or head injury with loss of consciousness. 5. Meets DSM IV criteria for any major psychiatric disorder including psychosis, major depression and bipolar disorder. 6. Known history of or self-reported active alcohol and/ or substance abuse within the past three years. 7. Isolated living circumstances which would prohibit a study partner from providing sufficient and credible information about the participant. 8. Poorly controlled hypertension 9. Known Atrioventricular heart block, known heart block type I-III. 10. History of myocardial infarction or signs or symptoms of unstable coronary artery disease within the last year (including revascularization procedure/angioplasty). 11. Severe pulmonary disease (including chronic obstructive pulmonary disease) requiring more than 2 hospitalizations within the past year. 12. Untreated obstructive sleep apnea. 13. Any thyroid disease (unless euthyroid on treatment for at least 6 months prior to screening). 14. Active neoplastic disease (except for skin tumors other than melanoma) within five years. 15. Absolute lymphocytopenia of \<1,000/mm3, or a history of lymphocytopenia within the past two years. 16. Absolute neutropenia of \<1,000/mm3, or a history of neutropenia within the past two years. 17. History of/ or current thromboembolism (including deep venous thrombosis). 18. Any clinically significant hepatic or renal disease (including presence of Hepatitis B or C surface antigen or an elevated transaminase levels of greater than 2x the upper limit of normal (ULN) or creatinine greater than 1.5 x upper limit of normal (ULN)). 19. Clinically significant hematologic or coagulation disorder including any unexplained anemia, or a platelet count less than 100,000/µL at screening. 20. Use of any investigational drug within 30 days or within five half-lives of the investigational agent, whichever is longer. 21. Unwilling or unable to undergo CT or MRI imaging. 22. In the opinion of the investigator, participation would not be in the best interest of the subject. 23. Subjects with CYP2C9\*3/\*3 genotyping
Contact & Investigator
Marwan N Sabbagh, MD
PRINCIPAL INVESTIGATOR
St. Josep's Hospital and Medical Center, Phoenix
Frequently Asked Questions
Who can join the NCT06639282 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 85 Years, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06639282 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06639282 currently recruiting?
Yes, NCT06639282 is actively recruiting participants. Contact the research team at Marwan.Sabbagh@CommonSpirit.org for enrollment information.
Where is the NCT06639282 trial being conducted?
This trial is being conducted at Phoenix, United States.
Who is sponsoring the NCT06639282 clinical trial?
NCT06639282 is sponsored by St. Joseph's Hospital and Medical Center, Phoenix. The principal investigator is Marwan N Sabbagh, MD at St. Josep's Hospital and Medical Center, Phoenix. The trial plans to enroll 105 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.